Medicare Enrolled
Dr. Devarajan Iyengar, M.D.
Hematology & Oncology · Bayonne, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Iyengar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iyengar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Iyengar
Dr. Devarajan Iyengar is a hematology & oncology specialist in Bayonne, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Iyengar performed 66,974 Medicare services across 2,464 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iyengar received a total of $3,158 from 45 pharmaceutical and/or device companies across 154 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iyengar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 17% volume in NJ
$3,158 industry payments
Medicare Practice Summary
Medicare Utilization ↗66,974
Medicare services
Top 17% in NJ for hematology & oncology
2,464
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,349 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
30,500 | $0 | $1 |
| Pembrolizumab injection (Keytruda) | 8,223 | $43 | $120 |
| Denosumab injection (Prolia/Xgeva) | 7,474 | $18 | $43 |
| Anti-nausea injection (ondansetron/Zofran) | 4,884 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,120 | $0 | $0 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,959 | $8 | $24 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,624 | $7 | $8 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
1,192 | $12 | $40 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,146 | $109 | $302 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
763 | $79 | $140 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
691 | $27 | $92 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
673 | $1 | $3 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
665 | $104 | $285 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
607 | $26 | $91 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
420 | $59 | $215 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
416 | $1 | $3 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
411 | $18 | $60 |
| Central venous tube declotting A procedure to clear a blockage or clot from a central venous catheter to restore its function. |
372 | $31 | $95 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
344 | $154 | $405 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
287 | $14 | $53 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
260 | $1 | $1 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
251 | $3 | $11 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
239 | $123 | $422 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
218 | $1 | $1 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
217 | $19 | $63 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
148 | $29 | $90 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
141 | $68 | $237 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
130 | $12 | $59 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
109 | $49 | $125 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
99 | $148 | $555 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
91 | $2 | $6 |
| New patient office visit, complex (60-74 min) | 54 | $191 | $575 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
49 | $1 | $5 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
45 | $185 | $760 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
36 | $69 | $199 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
32 | $4 | $15 |
| Iron dextran injection, 50 mg An injection containing 50 mg of iron dextran administered to the patient. |
26 | $13 | $33 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
23 | $71 | $202 |
| Home health plan of care certification Certification by a physician or allowed practitioner for Medicare-covered home health services under a home health plan of care. This includes contacting the home health agency and reviewing reports of patient status required by physicians. |
22 | $47 | $200 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
13 | $28 | $78 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.1% high complexity
82.3% medium
13.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,158
Total received (2018-2024)
Avg $451/year across 7 years
Bottom 49% in NJ for hematology & oncology
45
Companies
154
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,419 (76.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$739 (23.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$676
2023
$516
2022
$101
2021
$640
2020
$357
2019
$571
2018
$297
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$237
PFIZER INC.
$93
Merck Sharp & Dohme LLC
$70
Janssen Biotech, Inc.
$64
Lilly USA, LLC
$51
GENZYME CORPORATION
$40
Celgene Corporation
$30
Rigel Pharmaceuticals, Inc.
$23
TerSera Therapeutics LLC
$19
Azurity Pharmaceuticals, Inc.
$17
Eisai Inc.
$16
Regeneron Healthcare Solutions, Inc.
$16
Top 3 companies account for 59.1% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$360
Janssen Biotech, Inc.
$359
PFIZER INC.
$252
Astellas Pharma US Inc
$222
Exelixis Inc.
$175
Merck Sharp & Dohme Corporation
$156
Bayer HealthCare Pharmaceuticals Inc.
$152
Lilly USA, LLC
$133
Merck Sharp & Dohme LLC
$116
ARRAY BIOPHARMA INC
$91
Boehringer Ingelheim Pharmaceuticals, Inc.
$89
E.R. Squibb & Sons, L.L.C.
$86
Pharmacyclics LLC, An AbbVie Company
$85
Janssen Products, LP
$77
Celgene Corporation
$72
GENZYME CORPORATION
$56
Janssen Scientific Affairs, LLC
$50
Novartis Pharmaceuticals Corporation
$50
Novocure Inc.
$48
Regeneron Healthcare Solutions, Inc.
$47
Lexicon Pharmaceuticals, Inc.
$47
AbbVie Inc.
$43
Foundation Medicine, Inc.
$36
Myovant Sciences Inc.
$26
Rigel Pharmaceuticals, Inc.
$23
Apellis Pharmaceuticals, Inc.
$22
TerSera Therapeutics LLC
$19
AVEO Pharmaceuticals, Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
JAZZ PHARMACEUTICALS INC.
$19
Sirtex Medical Inc
$17
Azurity Pharmaceuticals, Inc.
$17
Eisai Inc.
$16
Celltrion USA Inc.
$16
Genentech USA, Inc.
$16
Octapharma USA, Inc.
$15
Daiichi Sankyo Inc.
$15
Incyte Corporation
$14
Ipsen Biopharmaceuticals, Inc
$13
EMD Serono, Inc.
$13
Teva Pharmaceuticals USA, Inc.
$12
Alexion Pharmaceuticals, Inc.
$12
Gilead Sciences, Inc.
$12
TESARO, Inc.
$12
AstraZeneca Pharmaceuticals LP
$11
Top 3 companies account for 30.8% of all-time payments
Associated products mentioned in payments ›
BRAFTOVI · Bavencio · CABOMETYX · COSELA · CREON · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ERBITUX · ERLEADA · EVENITY · Empaveli · Erleada · FOTIVDA · FOUNDATIONONE · GILOTRIF · IBRANCE · IMBRUVICA · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · Nplate · Nubeqa · OPDIVO · ORGOVYX · OXBRYTA · Optune · PADCEV · PANZYGA · PIQRAY · PROMACTA · Padcev · Prolia · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · Stivarga · Truxima · ULTOMIRIS · VEGZELMA · VENCLEXTA · VERZENIO · VIVIMUSTA · XALKORI · XTANDI · Xermelo · Xofigo · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
745
Per 100K population
104.9
County median income
$90,032
Nearest hospital
CAREPOINT HEALTH - BAYONNE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Iyengar is a mixed practice specialist, with above-average Medicare volume (top 17% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Iyengar experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Iyengar performed 30,500 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iyengar receive payments from pharmaceutical companies?
Yes. Dr. Iyengar received a total of $3,158 from 45 companies across 154 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iyengar's costs compare to other hematology & oncology specialists in Bayonne?
Dr. Iyengar's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iyengar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Bayonne
Browse hematology & oncology specialists in Bayonne ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology